Citalopram treatment of social anxiety disorder with comorbid major depression
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Treatment of patients with both social anxiety disorder and major depression has been little studied although social anxiety disorder and depression frequently co-occur. Each disorder has been shown to respond to serotonin reuptake inhibitor treatment. Objectives of this study were to characterize a sample of these comorbid patients and to assess response to treatment with citalopram. Patients with primary DSM-IV generalized subtype of social anxiety disorder and comorbid major depression (N = 21) were assessed for symptoms of each disorder, including atypical depressive features, and functional impairment. Patients were treated with a flexible dose of open label citalopram for 12 weeks. Response rates for the intention-to-treat sample at week 12 were 14/21 (66.7%) for social anxiety disorder and 16/21 (76.2%) for depression. All continuous measures of social anxiety, depression, and functional impairment improved significantly with treatment, but depression symptoms responded more rapidly and more completely than social anxiety symptoms. Mean dose of citalopram at study endpoint was 37.6 mg/day. Only three patients (14.3%) fulfilled DSM-IV criteria for atypical features of depression, although 18 (85.7%) fulfilled the criterion for interpersonal rejection sensitivity. Citalopram treatment may benefit patients with primary social anxiety disorder and comorbid major depression, and it should be further studied in controlled trials. Improvement in social anxiety disorder symptoms lagged behind improvement in depression, and greater than 12 weeks of treatment may be required to assess full social anxiety response in patients with comorbid depression. The overlap of social anxiety disorder with atypical features of depression may primarily be due to the shared feature of rejection sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Self-citationSchneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142
Stein, M. B., Fuetsch, M., Müller, N., Höfler, M., Lieb, R., & Wittchen, H.-U. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.3.251 · Cited by 573
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 2×
“, 1985] and selective responsivity to treatment with monoamine oxidase inhibitors over tricyclic antidepressants [Liebowitz et al., 1992; Quitkin et al., 1988; Simpson et al., 1998].”
BackgroundSelf-citationTreatment outcomes for primary care patients with major depression and lifetime anxiety disorders.
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.10.1293 · Cited by 312 · cited 2×
“, 1997] and more likely to drop out of treatment [Brown et al., 1996].”
BackgroundResultMajor depressive subtypes and treatment response
Fava, M., Uebelacker, L. A., Alpert, J. E., Nierenberg, A. A., Pava, J. A., & Rosenbaum, J. F. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00440-4 · Cited by 247
NELSON, E. C., GRANT, J. D., BUCHOLZ, K. K., GLOWINSKI, A., MADDEN, P. A. F., REICH, W., & HEATH, A. C. (2000) · Psychological Medicine · doi:10.1017/s0033291799002275 · Cited by 146 · cited 2×
“, 2001], and increased risk of suicidality and alcohol dependence [Nelson et al., 2000].”
BackgroundIs Interpersonal Psychotherapy Superior to Supportive Psychotherapy?
BROWN, W. A. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.11.1509-a · Cited by 63
Cited by
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“CE C1, RG 4 1 Fawcett and Barkin (1998), Rudolph et al. (1998), Schneier et al. (2003), Brady and Clary (2003).”
BackgroundPrognostic Value of Anxiety and Depression in Patients With Chronic Heart Failure
Jiang, W., Kuchibhatla, M., Cuffe, M. S., Christopher, E. J., Alexander, J. D., Clary, G. L., Blazing, M. A., Gaulden, L. H., Califf, R. M., Krishnan, R. R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148138.25157.f9 · Cited by 264
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
BELZER, K., & SCHNEIER, F. R. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200409000-00003 · Cited by 235
Self-citationComorbidity in social anxiety disorder: diagnostic and therapeutic challenges
Koyuncu, A., İnce, E., Ertekin, E., & Tükel, R. (2019) · Drugs in Context · doi:10.7573/dic.212573 · Cited by 216
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99
Self-citationAnxiety Disorders and Depression Comorbidity
Huppert, J. D. (2008) · Oxford Handbooks Online · doi:10.1093/oxfordhb/9780195307030.013.0044 · Cited by 37
Rozen, N., & Aderka, I. M. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101874 · Cited by 5
Steiner, A. J., Wright, S. M., Kuhn, T., & IsHak, W. W. (2017) · Applied Research in Quality of Life · doi:10.1007/s11482-016-9485-4 · Cited by 3
Metadata
- Authors
- Schneier, F. R., Blanco, C., Campeas, R., Lewis-Fernandez, R., Lin, S.-H., Marshall, R., Schmidt, A. B., Sanchez-Lacay, J. A., Simpson, H. B., & Liebowitz, M. R.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2003
- Volume
- 17
- Issue
- 4
- Pages
- 191-196
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W2034849561
- Cited by
- 56
- References
- 8
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.